SCHEMBL11889331

SCHEMBL11889331

CNc1cc(-c2cccnc2Nc2c(C)ccc3c(Nc4ccc(Cl)c(C(F)(F)F)c4)nccc23)ncn1

nearest known ligand 0.75

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.75
KDR P35968 8/20 0.75
LCK P06239 7/20 0.75
TEK Q02763 7/20 0.75
MAPK14 Q16539 2/20 0.66
RAF1 P04049 2/20 0.47
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
FLT1 P17948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11889333 0.91 BRAF (0.74) BRAFKDRLCKTEKMAPK14
SCHEMBL11889023 0.90 BRAF (0.83) BRAFKDRLCKTEKMAPK14
SCHEMBL11889300 0.90 BRAF (0.83) BRAFKDRLCKTEKMAPK14
SCHEMBL2516061 0.88 TEK (0.74) BRAFKDRLCKTEKMAPK14
SCHEMBL2514587 0.87 BRAF (0.82) BRAFKDRLCKTEKMAPK14
SCHEMBL11889317 0.87 TEK (0.79) BRAFKDRLCKTEKMAPK14
SCHEMBL2517955 0.86 BRAF (1.00) BRAFKDRLCKTEKMAPK14
SCHEMBL11889205 0.86 BRAF (0.78) BRAFKDRLCKTEKMAPK14
SCHEMBL11889511 0.85 BRAF (0.83) BRAFKDRLCKTEKMAPK14
SCHEMBL11888951 0.83 BRAF (0.84) BRAFKDRLCKTEKMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976836-B9 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2013-02-06 EP disclosed
EP-1976836-B1 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2012-08-22 EP disclosed
EP-2481729-A1 Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases Amgen Inc. (US) 2012-08-01 EP disclosed